Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15157579 | 0.85 | TSHR (0.45) | TSHRPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL8185898 | 0.82 | CYP19A1 (0.41) | TSHRADH1BADH1CADH1APPARG | |
| SCHEMBL8174510 | 0.81 | ADH1B (0.38) | TSHRADH1BADH1CADH1ATDP1 | |
| SCHEMBL19257405 | 0.79 | SMN1; SMN2 (0.42) | TSHRPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL295774 | 0.78 | — | — | |
| SCHEMBL3194735 | 0.78 | TSHR (0.43) | TSHRPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL7489413 | 0.77 | EPHX2 (0.50) | TSHRADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL243431 | 0.77 | TSHR (0.56) | TSHRPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL125438 | 0.77 | TSHR (0.42) | TSHRPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL5735543 | 0.77 | LMNA (0.39) | TSHRADH1BADH1CADH1APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479579-B2 | Therapeutic compounds and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-10-25 | — | — | US | disclosed |
| US-20210277055-A1 | THERAPEUTIC COMPOUNDS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-09-09 | — | — | US | disclosed |
| EP-0936218-B1 | BENZIMIDAZOLE DERIVATIVES | MOCHIDA PHARM CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6387938-B1 | Benzimidazole derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| EP-0936218-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
| EP-0080119-B1 | PROCESS FOR THE PREPARATION OF N-FORMYL-ALPHA-AMINO-ACID ESTERS | BASF Aktiengesellschaft (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0080119-A1 | Process for the preparation of N-formyl-alpha-amino-acid esters | BASF Aktiengesellschaft (DE) | 1983-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479579-B2 | Therapeutic compounds and methods | SNCA, PARK7, PSEN2 | TSHR 1993/4885ADH1B 333/4885ADH1C 1723/4885 |
| US-20210277055-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SNCA, PARK7, PSEN2 | TSHR 1993/4885ADH1B 333/4885ADH1C 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.